Back to top

Analyst Blog

Swiss pharmaceutical giant Novartis (NVS - Analyst Report) recently announced that it intends to present key data from studies in patients suffering from hematologic diseases and breast cancer this December. The data, containing more than 140 abstracts, will be presented by Novartis at the American Society of Hematology (ASH) and the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

Hematology

An important readout from the Hematology segment will be the presentation of two-year, follow-up data from phase III trials of Jakavi (ruxolitinib). Jakavi is being developed for the treatment of myelofibrosis. We note that Novartis licensed Jakavi from Incyte Corporation (INCY - Analyst Report) for the development and commercialization of the drug in ex-US markets.

The Hematology segment will also include two-year follow-up data from a study which is evaluating patients suffering from Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. The patients had switched to Novartis’ Tasigna after long-term treatment with the company’s other hematology drug Glivec  to achieve a deeper molecular response.

Novartis will be presenting updated data on Exjade (deferasirox) as a treatment of non-transfusion-dependent thalassemia (NTDT). We note that earlier in the month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had issued a positive opinion for approving Exjade for the NTDT indication. The company will also present new data from another study on the drug, where it is being developed for the removal of cardiac iron in Beta-thalassemia major. The Hematology segment also includes data presentation from other clinical trials on CTL019 (CART-19), PKC412 (midostaurin) and LBH589 (panobinostat), among others.  

The hematology market currently has players like Abbott Laboratories (ABT - Analyst Report).

Breast Cancer

Novartis is also engaged in research and development efforts for the treatment of breast cancer. The company currently has several candidates in this segment. Novartis will present data from a phase II clinical trial on Afinitor in combination with fulvestrant. The study is evaluating the combination in women suffering from HR+ advanced breast cancer who have progressed on a previous endocrine therapy.

Novartis will also present data from an additional phase II study on Afinitor in combination with Femara and from a phase III trial of Afinitor in combination with Pfizer Inc.’s (PFE - Analyst Report) Aromasin. Novartis estimates that Afinitor has the potential to generate $2 billion alone in advanced breast cancer by 2017.

Other important data readouts in breast cancer studies include data from a pre-clinical data from LBH589, a phase I study of BYL719 and a phase III randomized study of PI3K inhibitor BKM120.

We remind investors that companies like Roche Holding (RHHBY - Analyst Report) are already in the market targeting breast cancer.

Currently we have a Neutral recommendation on Novartis. The company carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 26.97 +10.13%
CENTURY ALU… CENX 27.08 +8.41%
BANCO DO BR… BDORY 16.74 +7.79%
CANADIAN SO… CSIQ 38.20 +7.79%
WILLDAN GRO… WLDN 11.40 +6.05%